Grilley-Olson, J. E., Allred, J. B., Schuetze, S., Davis, E. J., Wagner, M. J., Poklepovic, A. S., … Schwartz, G. K. (2023). A multicenter phase II study of cabozantinib plus nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Grilley-Olson, Juneko E., Jacob B. Allred, Scott Schuetze, Elizabeth J. Davis, Michael J. Wagner, Andrew Stewart Poklepovic, Blake Waechter, et al. “A multicenter phase II study of cabozantinib plus nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Grilley-Olson JE, Allred JB, Schuetze S, Davis EJ, Wagner MJ, Poklepovic AS, et al. A multicenter phase II study of cabozantinib plus nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Grilley-Olson, Juneko E., et al. “A multicenter phase II study of cabozantinib plus nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Grilley-Olson JE, Allred JB, Schuetze S, Davis EJ, Wagner MJ, Poklepovic AS, Waechter B, Riedel RF, Welliver MX, Berg SA, George S, Robinson SI, Googe PB, D’Angelo SP, Schwartz GK. A multicenter phase II study of cabozantinib plus nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902). JOURNAL OF CLINICAL ONCOLOGY. 2023.